New

Regeneron

The AI engine Fit Assessment

Beta

The company demonstrates pharmaceutical R&D activity evidenced by patenting methods for treating chronic sinusitis with nasal polyps using an IL-based composition, indicating involvement in pharma technology development. Check Source

Blurb

Regeneron Pharmaceuticals specializes in the discovery, development, and commercialization of innovative medicines.

HQ Location

Tarrytown (United States)

Founded

1988

Employees

10000+

Total funding raised

$15.93M

Funding Status

Post-IPO Equity, $2.03M, July 11, 2024

At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in.



Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media.



An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media.